Roivant Sciences (ROIV) investor relations material

Strategic direction, evolution, and business transformation

• Entering a new decade with a streamlined, focused approach on late-stage development and commercialization of high-value programs, emphasizing execution, capital efficiency, and shareholder value.

• Well-capitalized with $4.4B in cash, funded through profitability, $1.5B in share repurchases completed, and $500M more authorized.

• Homegrown leadership and dynamic, entrepreneurial culture drive rapid adaptation, creative product development, and a lean, agile organization.

• Portfolio targets tractable, high unmet-need orphan and specialty indications with multi-blockbuster potential, focusing on specialty prescriber bases and limited competition.

• Actively seeking to expand pipeline with late-stage programs and new indications, leveraging strong BD and R&D teams and $2B reserved for opportunistic expansion.

Pipeline progress and clinical development highlights

• Brepocitinib: NDA for dermatomyositis (DM) expected early 2026, commercial launch planned for early 2027; NIU phase III topline data expected 2H 2026, and cutaneous sarcoidosis phase II data in 1H 2026.

• IMVT-1402: Registrational data in Graves' disease expected by 2027, D2T RA and CLE pivotal data in 2026, and best-in-class potential in MG, CIDP, and SjD with pivotal data in 2027–2028.

• Mosliciguat: Phase II PHocus study in PH-ILD on track for topline data in 2H 2026, aiming to be the first non-treprostinil option and first-in-class inhaled sGC activator.

• Eight pivotal readouts and three proof-of-concept studies across multiple indications expected in the next 36 months.

• Commercial launches planned for DM, NIU, GD, and MG, with infrastructure and prescriber relationships already established.

Commercial and financial outlook

• $15B+ peak revenue potential across brepocitinib, Immunovant, and mosliciguat franchises, with stacked launches from 2027 onward and significant room for growth as new indications are pursued.

• SG&A and R&D spend fully funded, with disciplined capital deployment, non-GAAP R&D in the low-to-mid $600M range, and Immunovant financing extending cash runway to IMVT-1402 launch.

• Focused on capital efficiency: increased cash balance, net cash returned to shareholders, and doubled share price since going public.

• Commercial strategy leverages specialty networks, limited distribution, and patient support, with scalable infrastructure for future launches.

• $2B available for new opportunities and pipeline expansion, with minimal dilution.